Praxis Precision Medicines to Participate in Five Upcoming Investor Conferences

About this update from Praxis Precision Medicines, Inc.

BOSTON , March 04, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines , Inc. (NASDAQ: PRAX ), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that it will be participating in five upcoming investor conferences: Praxis management will be presenting a corporate overview at the 45 th Annual TD Cowen Health Care Conference , taking place at the Boston Marriott Copley Place in Boston on Wednesday, March 5, 2025 at 9:10a.m. EDT . A live webcast of the event will be available through this link . Praxis management will also be participating in a fireside chat at the Leerink Partners Global Healthcare Conference , taking place at the W South Beach Hotel in Miami on Monday, March 10, 2025 at 3:40p.m. EDT . A live webcast of the event will be available through this link . Praxis management will also be participating in one-on-one investor meetings at the Jefferies Biotech on the Bay Summit , taking place at the Ritz Carlton South Beach Hotel in Miami on Tuesday, March 11, 2025 . Praxis management will also be participating in a fireside chat at the Barclays 27 th Annual Global Healthcare Conference , taking place at the Loews Miami South Beach Hotel in Miami on Wednesday, March 12, 2025 at 2:30p.m. EDT . A live webcast of the event will be available through this l ink . Praxis management will also be participating in a fireside chat at the UBS Virtual CNS Day , taking place on March 17, 2025 at 9:30a.m. EDT . A live webcast of the event will be available through this link . The Company will be available for one-on-one meetings during all events. Interested investors should contact their respective representatives to request meetings. Replays of the webcasted events will also be available through the “ Events & Presentations ” page under the “ Investors + Media ” section of the company’s website for 90 days. About Praxis Praxis Precision Medicines is a clinical-stage biopharmaceutical company translating insights from genetic epilepsies into the development of therapies for CNS disorders characterized by neuronal excitation-inhibition imbalance. Praxis is applying genetic insights to the discovery and development of therapies for rare and more prevalent neurological disorders through our proprietary small molecule platform, Cerebrum™, and antisense oligonucleotide (ASO) platform, Solidus™, using our understanding of shared biological targets and circuits in the brain. Praxis has established a diversified, multimodal CNS portfolio including multiple programs across movement disorders and epilepsy, with four clinical-stage product candidates. For more information, please visit www.praxismedicines.com and follow us on Facebook , LinkedIn and Twitter/X . Investor Contact: Praxis Precision Medicines [email protected] 857-702-9452 Media Contact: Dan Ferry Life Science Advisors [email protected] 617-430-7576 Source: Praxis Precision Medicines, Inc.

View stock analysis, news, and events for Praxis Precision Medicines, Inc.